Skip to main content

KILL New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

 

Genentech requests that their press release NewsItemId: 20240125093104 “New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)” be killed.

The release was issued prematurely by Genentech.

A replacement release will be issued at a later date.

Contacts

Media Contact:

Shirley Dang, (650) 467-6800

Advocacy Contact:

Danielle Haney, (240) 805-4810

Investor Contacts:

Loren Kalm, (650) 225-3217

Bruno Eschli, +41 61 687 5284

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  252.54
+1.35 (0.54%)
AAPL  333.39
-3.61 (-1.07%)
AMD  548.73
+3.64 (0.67%)
BAC  58.05
-0.13 (-0.22%)
GOOG  346.53
+2.85 (0.83%)
META  672.85
-9.46 (-1.39%)
MSFT  492.69
-5.06 (-1.02%)
NVDA  219.96
+0.62 (0.28%)
ORCL  145.40
-5.19 (-3.45%)
TSLA  363.72
-2.48 (-0.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.